中东和非洲膀胱癌治疗和诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按癌症类型、诊断和治疗以及地理划分

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 5.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于对膀胱疾病和可用疗法的认识不断提高,以及药物开发的不断创新,膀胱癌治疗和诊断市场将出现快速增长。根据国际癌症研究机构的数据,膀胱癌是全球第 6 位最常见的男性癌症,也是全球第 9 大癌症死亡原因。根据 Globocan 2018 年的数据,在中东和非洲 (MEA) 地区的国家,如阿拉伯联合酋长国 (UAE),膀胱癌是第 8 大最常见的癌症类型。

近年来,对膀胱疾病及其管理的认识有了很大的提高,特别是在中东和非洲等发展中地区。此外,不同疗法(例如癌症治疗中的免疫疗法)的兴起重新引起了符合条件的患者的兴趣,因为它是一种最近开发的治疗方式,并且与放射疗法和化学疗法相比具有较低的副作用,而放射疗法和化学疗法是膀胱癌管理中的常规治疗选择.

因此,人们对膀胱癌和相关疗法的认识不断提高,预计中东和非洲膀胱癌治疗和诊断市场将在未来增长。 

Scope of the report

As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market.

By Cancer Type
Transitional Cell Bladder Cancer
Superficial Bladder Cancer
Invasive Bladder Cancer
Other Rare Types
By Diagnostics and Therapeutics
By Therapeutics
Chemotherapy
Immunotherapy
Radiation Therapy
Surgery
By Diagnostics
Cytoscopy
Biopsy
Urinalysis
Others
Geography
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa

Report scope can be customized per your requirements. Click here.

主要市场趋势

放射治疗有望占据很大的市场份额

膀胱癌是高度流行的疾病,并且随着年龄的增长而增加。根据 2018 年 Globocan 的报告,预计未来中东和非洲地区的膀胱癌发病率将会增加。最先进的膀胱癌治疗方式包括免疫疗法,但在膀胱癌中最广泛使用的方式是放射治疗。这是由于放射疗法在各种形式的癌症中的历史使用普遍性,还因为化学疗法与低特异性和副作用有关。与膀胱癌管理中的其他治疗方式相比,放射治疗在剂量频率和定价方面也提供了同类最佳的疗效。放射治疗的进步和膀胱癌患者数量的预期增加预计将有助于该市场的增长。

Graph.png

竞争格局

由于过去几十年的经济增长等因素,大多数全球参与者都出现在中东和非洲 (MEA) 的海湾合作委员会 (GCC) 地区。

非洲地区由一些发展中国家和欠发达国家组成。由于缺乏必要的资金,这些国家的医疗保健系统仍然结构不完善和稳定。然而,随着最近的外国投资,该地区的医疗保健状况正在改善。因此,该地区的市场虽然不大,但预计未来会增长。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies

      2. 4.2.2 Innovations in Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Rise in the number of Patent Expirations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Transitional Cell Bladder Cancer

      2. 5.1.2 Superficial Bladder Cancer

      3. 5.1.3 Invasive Bladder Cancer

      4. 5.1.4 Other Rare Types

    2. 5.2 By Diagnostics and Therapeutics

      1. 5.2.1 By Therapeutics

        1. 5.2.1.1 Chemotherapy

        2. 5.2.1.2 Immunotherapy

        3. 5.2.1.3 Radiation Therapy

        4. 5.2.1.4 Surgery

      2. 5.2.2 By Diagnostics

        1. 5.2.2.1 Cytoscopy

        2. 5.2.2.2 Biopsy

        3. 5.2.2.3 Urinalysis

        4. 5.2.2.4 Others

    3. 5.3 Geography

      1. 5.3.1 Middle East and Africa

        1. 5.3.1.1 GCC

        2. 5.3.1.2 South Africa

        3. 5.3.1.3 Rest of Middle East and Africa

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc.

      2. 6.1.2 Bristol Myers Squibb

      3. 6.1.3 Eli Lilly and Co.

      4. 6.1.4 GlaxoSmithKline Plc.

      5. 6.1.5 Merck & Co., Inc.

      6. 6.1.6 Johnson and Johnson

      7. 6.1.7 Novartis AG

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Sanofi S.A.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA Bladder Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The MEA Bladder Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 5.6% over the next 5 years.

Pfizer Inc., Johnson and Johnson, AstraZeneca Plc., Bristol Myers Squibb, Merck & Co., Inc. are the major companies operating in MEA Bladder Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!